Interleukin-1 and the inflammasome as therapeutic targets in cardiovascular disease

A Abbate, S Toldo, C Marchetti, J Kron… - Circulation …, 2020 - Am Heart Assoc
The intracellular sensing protein termed NLRP3 (for NACHT, LRR, and PYD domains-
containing protein 3) forms a macromolecular structure called the NLRP3 inflammasome …

Inflammasome, pyroptosis, and cytokines in myocardial ischemia-reperfusion injury

S Toldo, AG Mauro, Z Cutter… - American Journal of …, 2018 - journals.physiology.org
Myocardial ischemia-reperfusion injury induces a sterile inflammatory response, leading to
further injury that contributes to the final infarct size. Locally released danger-associated …

Risk of cardiomyopathy and cardiac arrhythmias in patients with nonalcoholic fatty liver disease

QM Anstee, A Mantovani, H Tilg… - Nature Reviews …, 2018 - nature.com
Nonalcoholic fatty liver disease (NAFLD) is a common, progressive liver disease that affects
up to one-quarter of the adult population worldwide. The clinical and economic burden of …

The selective NLRP3-inflammasome inhibitor MCC950 reduces infarct size and preserves cardiac function in a pig model of myocardial infarction

GPJ Van Hout, L Bosch, GHJM Ellenbroek… - European heart …, 2017 - academic.oup.com
Aims Myocardial infarction (MI) triggers an intense inflammatory response that is associated
with infarct expansion and is detrimental for cardiac function. Interleukin (IL)-1β and IL-18 …

Inflammatory pathways in heart failure with preserved left ventricular ejection fraction: implications for future interventions

NR Pugliese, P Pellicori, F Filidei… - Cardiovascular …, 2022 - academic.oup.com
Many patients with symptoms and signs of heart failure have a left ventricular ejection
fraction≥ 50%, termed heart failure with preserved ejection fraction (HFpEF). HFpEF is a …

NFkappaB is a key player in the crosstalk between inflammation and cardiovascular diseases

A Fiordelisi, G Iaccarino, C Morisco, E Coscioni… - International journal of …, 2019 - mdpi.com
Inflammation is a key mechanism of cardiovascular diseases. It is an essential component of
atherosclerosis and a significant risk factor for the development of cardiovascular events. In …

Interleukin-1 blockade in recently decompensated systolic heart failure: results from REDHART (Recently Decompensated Heart Failure Anakinra Response Trial)

BW Van Tassell, J Canada, S Carbone… - Circulation: Heart …, 2017 - Am Heart Assoc
Background An enhanced inflammatory response predicts worse outcomes in heart failure
(HF). We hypothesized that administration of IL-1 (interleukin-1) receptor antagonist …

A review of interleukin-1 in heart disease: where do we stand today?

Y Szekely, Y Arbel - Cardiology and therapy, 2018 - Springer
Cardiovascular diseases are the leading cause of death worldwide. Research in the last two
decades has emphasized the inflammatory process as a key component in the …

Inflammatory and fibrotic responses of cardiac fibroblasts to myocardial damage associated molecular patterns (DAMPs)

NA Turner - Journal of molecular and cellular cardiology, 2016 - Elsevier
Cardiac fibroblasts (CF) are well-established as key regulators of extracellular matrix (ECM)
turnover in the context of myocardial remodelling and fibrosis. Recently, this cell type has …

The role of pro-Inflammatory cytokines in the pathogenesis of cardiovascular disease

H Zhang, NS Dhalla - International Journal of Molecular Sciences, 2024 - mdpi.com
With cardiovascular disease (CVD) being a primary source of global morbidity and mortality,
it is crucial that we understand the molecular pathophysiological mechanisms at play …